The German Cancer Research Center [30] reported that immunotherapy fails to provide a survival benefit in patients with NASH/NAFLD, owing to an accumulation of abnormal CD8 + /PD-1 + T cells within the liver. This evidence concerns the gene CD8A and metabolic dysfunction-associated steatotic liver disease.